Canada’s Drug Agency | Drugs, Health Technologies and Systems.

bevacizumab

Details

Files
Generic Name:
bevacizumab
Project Status:
Pending
Therapeutic Area:
Gynecological cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0383-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
With chemotherapy in locally advanced or metastatic endometrial cancer after disease progression on at least one prior line of therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Files

Proposed Scope View PDF
Last Updated : July 9, 2025